文献速递肿瘤 PET/CT

基线及早期18F-FDG PET/CT的TMTV与Dmax在免疫检查点阻断治疗的转移性皮肤黑色素瘤中的预后价值

Prognostic value of TMTV and Dmax calculated from 18F-fluorodeoxyglucose positron emission tomography images in metastatic cutaneous melanoma treated with immune checkpoint blockade.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-17

本研究回顾性纳入两中心143例接受免疫检查点阻断(ICB)治疗的转移性皮肤黑色素瘤(CM)患者,基于基线(PET0)和早期随访(PET1,治疗后9-12周)[18F]FDG-PET/CT计算总代谢肿瘤体积(TMTV)、最大病灶间距(Dmax)及其变化。结果显示PET0时Dmax高于中位数与更差的无进展生存(PFS)和总生存(OS)独立相关,PET0至PET1间TMTV和Dmax稳定或增加(ΔTMTV和ΔDmax≥0%)与显著更差结局相关。

要点

  • 基线Dmax高于中位数与更差PFS(HR=1.67)和OS(HR=2.03)独立相关。
  • PET0至PET1间ΔTMTV和ΔDmax≥0%与显著更差结局相关。
  • 联合基线TMTV、Dmax及ΔTMTV、ΔDmax可将患者分为三个预后不同的风险组。

核心结论

  • 基线TMTV和Dmax及其早期变化是接受ICB治疗的转移性CM的强预后标志物。

研究设计与样本

  • 回顾性研究,纳入两中心2016-2023年143例接受ICB治疗的转移性CM患者。
  • 采用PERCIST法在基线(PET0)和早期随访(PET1,治疗后9-12周)[18F]FDG-PET/CT上分割肿瘤病灶并计算TMTV、Dmax及其变化。

主要发现

  • PET0时Dmax高于中位数与更差PFS独立相关(HR=1.67;95%CI:1.03-2.71;p=0.036)。
  • PET0时Dmax高于中位数与更差OS独立相关(HR=2.03;95%CI:1.20-3.43;p=0.009)。
  • PET0至PET1间ΔTMTV和ΔDmax≥0%与显著更差结局相关。
  • 分别使用PET0的TMTV和Dmax以及ΔTMTV和ΔDmax可将患者分层为三个预后不同的风险组。

关键数值与推荐

  • Dmax以中位数分组,高于中位数定义为升高。
  • ΔTMTV和ΔDmax≥0%定义为稳定或增加。

临床怎么用

  • 基线及早期[18F]FDG-PET/CT的TMTV和Dmax可用于接受ICB治疗的转移性CM的早期风险分层。
  • 整合上述指标可能有助于制定个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cutaneous melanoma (CM) is an aggressive malignancy with rising incidence. Immune checkpoint blockades (ICBs), particularly anti-PD-1 therapies, have improved survival in metastatic CM. However, many patients show primary resistance or develop progression after initial benefit. Early identification of patients likely to benefit remains a clinical challenge. Total Metabolic Tumor Volume (TMTV) and the maximum distance between two lesions (Dmax), derived from baseline [18F]FDG-PET/CT, have shown prognostic relevance in other cancers. This study evaluates their prognostic value in metastatic CM. METHODS: This retrospective study included 143 patients with metastatic CM treated with ICBs (2016-2023) across two centers. Tumor lesions were segmented using PERCIST procedure on baseline (PET0) and early follow-up (PET1, 9-12 weeks post-treatment) [18F]FDG-PET/CT. TMTV, Dmax, and their changes (ΔTMTV, ΔDmax) were calculated. Associations with progression-free survival (PFS) and overall survival (OS) were assessed, including in multivariable analyses. RESULTS: Elevated Dmax (above median) at PET0 was independently linked to poorer PFS (HR = 1.67; 95% confidence interval (CI): 1.03-2.71; p = 0.036) and OS (HR = 2.03; 95% CI: 1.20-3.43; p = 0.009). Stable or increased TMTV and Dmax between PET0 and PET1 (ΔTMTV and ΔDmax ≥ 0%) correlated with significantly worse outcomes. Using PET0 TMTV and Dmax, as well as ΔTMTV and ΔDmax considered separately, allowed stratification into three risk groups with distinct prognoses. CONCLUSION: Baseline TMTV and Dmax, along with their early changes, are strong prognostic markers in metastatic CM treated with ICBs. Their integration into clinical practice may enhance early risk stratification and inform personalized therapeutic strategies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Amrane K, Cabarrou B, Le Meur C, et al. Prognostic value of TMTV and Dmax calculated from 18F-fluorodeoxyglucose positron emission tomography images in metastatic cutaneous melanoma treated with immune checkpoint blockade. Eur J Nucl Med Mol Imaging. 2026. PMID: 41699280. doi:10.1007/s00259-025-07727-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。